129 related articles for article (PubMed ID: 19092678)
21. Cardiac hormones target nuclear oncogenes c-Fos and c-Jun in carcinoma cells.
Manimala NJ; Frost CD; Lane ML; Higuera M; Beg R; Vesely DL
Eur J Clin Invest; 2013 Nov; 43(11):1156-62. PubMed ID: 23992401
[TBL] [Abstract][Full Text] [Related]
22. Five cardiac hormones decrease the number of human small-cell lung cancer cells.
Vesely BA; Song S; Sanchez-Ramos J; Fitz SR; Alli AA; Solivan SM; Gower WR; Vesely DL
Eur J Clin Invest; 2005 Jun; 35(6):388-98. PubMed ID: 15948900
[TBL] [Abstract][Full Text] [Related]
23. Central role of β-catenin in anticancer effects of cardiac hormones.
Skelton WP; Skelton M; Vesely DL
Anticancer Res; 2013 Jun; 33(6):2409-14. PubMed ID: 23749889
[TBL] [Abstract][Full Text] [Related]
24. Cardiac hormones are c-Jun-N-terminal kinase 2-inhibiting peptides.
Lane ML; Santana O; Frost CD; Nguyen J; Guerrero J; Skelton WP; Skelton M; Vesely DL
Anticancer Res; 2012 Mar; 32(3):721-5. PubMed ID: 22399583
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor's activation of Ras is inhibited by four cardiac hormones.
Sun Y; Eichelbaum EJ; Lenz A; Wang H; Vesely DL
Eur J Clin Invest; 2010 May; 40(5):408-13. PubMed ID: 20353436
[TBL] [Abstract][Full Text] [Related]
26. Primary malignant tumors of the heart: four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells.
Vesely BA; Alli A; Song S; Sanchez-Ramos J; Fitz SR; Gower WR; Vesely DL
Cardiology; 2006; 105(4):226-33. PubMed ID: 16534199
[TBL] [Abstract][Full Text] [Related]
27. Potent selective inhibition of STAT 3 versus STAT 1 by cardiac hormones.
Lane ML; Frost CD; Nguyen JP; Skelton WP; Skelton M; Vesely DL
Mol Cell Biochem; 2012 Dec; 371(1-2):209-15. PubMed ID: 22965761
[TBL] [Abstract][Full Text] [Related]
28. Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via cyclic GMP.
Gower WR; Vesely BA; Alli AA; Vesely DL
Int J Gastrointest Cancer; 2005; 36(2):77-87. PubMed ID: 16648657
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of AKT in human pancreatic, renal and colorectal cancer cells by four cardiac hormones.
Skelton WP; Skelton M; Vesely DL
Anticancer Res; 2013 Mar; 33(3):785-90. PubMed ID: 23482745
[TBL] [Abstract][Full Text] [Related]
30. Twice-weekly intravenous treatment of pancreatic cancer with atrial natriuretic peptide and vessel dilator.
Lenz A; Sun Y; Eichelbaum EJ; Skelton WP; Pi G; Vesely DL
In Vivo; 2010; 24(2):125-9. PubMed ID: 20363982
[TBL] [Abstract][Full Text] [Related]
31. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells.
Sun Y; Eichelbaum EJ; Wang H; Vesely DL
Anticancer Res; 2007; 27(3B):1387-92. PubMed ID: 17595752
[TBL] [Abstract][Full Text] [Related]
32. Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis.
Vesely BA; Eichelbaum EJ; Alli AA; Sun Y; Gower WR; Vesely DL
Am J Med Sci; 2007 Nov; 334(5):342-9. PubMed ID: 18004088
[TBL] [Abstract][Full Text] [Related]
33. Vessel dilator and kaliuretic peptide inhibit ERK 1/2 activation in human prostate cancer cells.
Sun Y; Eichelbaum EJ; Wang H; Vesely DL
Anticancer Res; 2006; 26(5A):3217-22. PubMed ID: 17094432
[TBL] [Abstract][Full Text] [Related]
34. Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin.
Vesely DL; Perez-Lamboy GI; Schocken DD
Metabolism; 2000 Dec; 49(12):1592-7. PubMed ID: 11145122
[TBL] [Abstract][Full Text] [Related]
35. Cardiac hormones inhibit proliferation of pancreatic cancer but not normal cells.
Skelton WP; Pi G; Lenz A; Sun Y; Vesely DL
Eur J Clin Invest; 2010 Aug; 40(8):706-12. PubMed ID: 20546014
[TBL] [Abstract][Full Text] [Related]
36. Cardiac hormones activate ERK 1/2 kinases in human fibroblasts.
Sun Y; Eichelbaum EJ; Wang H; Vesely DL
Horm Metab Res; 2009 Mar; 41(3):197-201. PubMed ID: 18855305
[TBL] [Abstract][Full Text] [Related]
37. Four peptides decrease the number of human pancreatic adenocarcinoma cells.
Vesely BA; McAfee Q; Gower WR; Vesely DL
Eur J Clin Invest; 2003 Nov; 33(11):998-1005. PubMed ID: 14636304
[TBL] [Abstract][Full Text] [Related]
38. Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells.
Sun Y; Eichelbaum EJ; Wang H; Vesely DL
Anticancer Res; 2007; 27(6B):3813-8. PubMed ID: 18225537
[TBL] [Abstract][Full Text] [Related]
39. Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations.
Vesely DL; San Miguel GI; Hassan I; Schocken DD
Horm Metab Res; 2002 May; 34(5):245-9. PubMed ID: 12063637
[TBL] [Abstract][Full Text] [Related]
40. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells.
Sun Y; Eichelbaum EJ; Skelton WP; Lenz A; Wang H; Vesely DL
Anticancer Res; 2009 Apr; 29(4):971-5. PubMed ID: 19414334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
